Aligos Therapeutics Q3 EPS $(2.09) Beats $(2.28) Estimate, Sales $2.830M Miss $5.543M Estimate

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.09) per share which beat the analyst consensus estimate of $(2.28) by 8.33 percent. This is a 31.25 percent increase over losses of $(3.04) per share from the same period last year. The company reported quarterly sales of $2.830 million which missed the analyst consensus estimate of $5.543 million by 48.94 percent. This is a 281.92 percent increase over sales of $741.000 thousand the same period last year.